Why attend Cancer Progress?
Gain insights from provocative, frank and visionary panel discussions-no boring speeches or sales pitches!
Learn about the import and impact of the latest advancements in cancer research and treatments for patients, companies and payers
Access leading oncology innovators, industry executives and investors through Cancer Progress Partnering
With your generosity and support, we are proud to announce that Cancer Progress donated $20,000 to cancer-related and COVID-19 first-line responder charitable organizations in 2020. We look forward to making a significant contribution to these causes again in 2021.
Thank you for your support!
Keynote Speaker Day One
Engineering the Future: Next Gen Platforms in Oncology
Daniel S. Chen, MD, PhD
Tuesday, May 4, 2021 | 9:15 – 10:00 am EDT
Chief Medical Officer
Keynote Speaker Day Two
Off-the-shelf CAR-engineered NK cells for the treatment of cancer
Katy Rezvani, MD, PhD
Wednesday, May 5, 2021 | 9:15 – 10:00 am EDT
Principal Investigator, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
Cancer Progress Conference Panels Include...
Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors
Multifunctional Soluble Biologics: Binders, Binders Everywhere
Tumor Agnostic Development
Accelerated Development Paths
Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?
Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)
Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)
Cell Therapy in Solid Tumors: Freedom of the Open Road
Validating New Platforms: Clinical Pain, Commercial Gain
Counterpoint to Engineered Platforms: Less is More
China
Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!
Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML
Let’s Make a Deal in Oncology: What’s Behind the Doors & Who Has the Keys? Value Panel
Battle of the Modalities- The sequel
Cancer Progress 2020 Panel Summaries
As a preview of the good things to expect from Cancer Progress 2021, we’re excited to roll out summaries of select sessions from Cancer Progress 2020, starting with a summary of the panel “Paradigm Shifting Platforms II – Non-IO: Targeting Better, Targeting the Intractable” that highlights the key opportunities and challenges of non-IO targeted approaches and how even they cannot be thought of independently from IO.
Paradigm Shifting Platforms I –IO: Taking IO to the Next Level
Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable
Since 1989, Cancer Progress is the only oncology conference that facilitates discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives over three days of provocative, informative panel discussions. Pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and, for the first time ever, a partnering platform to enable meaningful connections and meetings with innovators, developers and investors.
Our 32nd Annual Meeting on May 4-6, 2021 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.
Thank you to our Cancer Progress 2021 Sponsors
Testimonials
Good array of opinions and technologies. Well curated
Andrew Allen, MD, PhD, President & CEO
Gritstone OncologyAs I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!
Michael G. King, Jr., Entrepreneur in Residence
Fortress Biotech Inc.When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts
Mark Simon, Managing Director
Torreya“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”
Noemi Rosa
Novartis“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”